Compounded tirzepatide doses: what the programs publish
Compounded tirzepatide is a pharmacy-made version that is not FDA-approved and is not Zepbound or Mounjaro. On the chart, 3 programs publish something about compounded tirzepatide dosing. Of those, one publishes a range: Mochi Health states 2.2 mg to 16.6 mg weekly at one price, according to GLP Chart's read of its published pages on August 31, 2026. There is no FDA dose schedule behind any of those numbers, because a dose schedule comes from a label and no compounded preparation has one.
What each program publishes about dose
| Program | What it publishes about dose | Read on |
|---|---|---|
| Mochi Health | 2.2 mg to 16.6 mg weekly, at one price. Its FAQ answers “does compound medication pricing vary by dose” with no. | Mochi Health FAQ, August 31, 2026 |
| Strut Health | A price per day rather than a dose: injectable at $4.97 a day on auto-refill and oral at $6.63. No dose is named at either price. | Strut Health pricing, August 31, 2026 |
| Henry Meds | A single monthly band with no dose attached to either end of it. | Henry Meds program terms, August 31, 2026 |
Mochi's top figure sits above the approved ceiling
The approved tirzepatide labels stop at 15 mg once weekly. Mochi publishes a range whose top is 16.6 mg. That is not a rule violation on its face, because a compounded product is not on those labels at all and the prescriber sets the dose.
The FDA has published on the general case. It says it has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the approved label, whether by using more in a single dose, dosing more often, or increasing the amount more quickly, and it tells prescribers to be vigilant when setting doses and titration schedules. Read the FDA's statement.
Ask for your dose in milligrams and get it in writing. Units on a syringe depend on the concentration the pharmacy filled, so the same unit count is a different dose at two pharmacies.
What federal rules permit
Compounding is permitted under federal compounding rules in limited circumstances. A compounded product is made by a licensed compounding pharmacy to a prescription; the FDA does not review it for safety, effectiveness or quality, and its formulation, including the salt form, can differ from the approved drug. Confirm the active ingredient and the pharmacy with the prescriber. The FDA's own compounding pages set out what a 503A pharmacy and a 503B outsourcing facility may each do.
Compare every compounded tirzepatide program at its maintenance price →
Frequently asked questions
Is there an official dose chart for compounded tirzepatide?
No. A dose chart comes from an FDA label and no compounded preparation has one. The approved tirzepatide labels stop at 15 mg a week, and a compounded ladder is set by the prescriber and the pharmacy rather than by a label.
Why does one program publish a range and another publish a price per day?
Because nobody makes them publish anything. Mochi states a 2.2 mg to 16.6 mg weekly range and one price across it. Strut Health publishes a daily rate and names no dose at all. Both are the program's own choice about what to disclose.
Is compounded tirzepatide legal?
It is permitted under federal compounding rules in limited circumstances: a state-licensed pharmacy preparing it against a valid prescription. That is not FDA approval, which no compounded drug has.
Does a higher dose cost more?
It depends on the program. Mochi publishes one price across its whole stated range. Others publish a band, and the chart prices every program at its ongoing maintenance cost so the bands are comparable.
This page answers what the programs publish and what the rules permit. It does not tell you which dose to take, and it makes no judgment about whether a compounded product is right for you. That conversation belongs with your prescriber.
Sources
Evidence checked August 31, 2026
Each clinical claim above links to the document it came from, so you can read the source instead of trusting us. GLP Chart has no medical reviewer, and does not borrow a name for one. What that means.
- Adverse event reports tied to compounded tirzepatide prescribed beyond the approved label, to faster titration schedules, and the FDA's guidance to prescribers on setting doses and titrationFDA's concerns with unapproved GLP-1 drugs used for weight loss
- What 503A and 503B compounding are, and the limited circumstances in which federal rules permit a pharmacy to compoundFDA, human drug compounding
- The approved tirzepatide dose ladder and 15 mg ceiling that a compounded preparation does not haveFDA prescribing information for Zepbound (DailyMed, revised August 2026)
